A Novel Approach to Cervical Cancer Therapy: A Short Review
Amir Sasan Mozaffari Nejad1, Farideh Kamarehei2, Amir Khodavirdipour3, Parvaneh Mehrbod4, Mohammad Yousef Alikhani2, *
Identifiers and Pagination:Year: 2023
E-location ID: e187494452303080
Publisher ID: e187494452303080
Article History:Received Date: 29/11/2022
Revision Received Date: 12/02/2023
Acceptance Date: 15/02/2023
Electronic publication date: 06/04/2023
Collection year: 2023
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cervical cancer is one of the most common cancers affecting women worldwide, and it occurs following persistent infection. Cervical cancer incidence is tightly linked to HPV infection (human papillomavirus), and particularly, type 16 and type 18 viruses cause the majority of cases. The common therapies for cervical cancer include surgery, chemotherapy, and radiation therapy, which are often invasive or unbearable treatment methods with many side effects. They just probably slow down the disease progression or alleviate any comorbid conditions, including vaginal bleeding and pain, which is called palliative care, while novel treatment approaches, especially virus-like particles and viral oncolysate, could eliminate these complications. In this review study, we have proposed a novel approach to cervical cancer therapy focused on utilizing Newcastle disease virus as viral oncolysate with a high potential of immunity induction and low side effects. Furthermore, we have attempted to shed some light on the perspectives of novel virus-based cervical cancer immunotherapy. Finally, we review the recent findings from basic and clinical studies and also discuss the usefulness and limitations of this approach, as well as the reasons why it is believed that viral oncolysate immunotherapy may be of relevance in the treatment of human cervical cancer.